.jpg)
Longevity Conferences 2023
January 19, 2023
Curated list of Longevity Conferences, where you can explore the latest research and developments in the field of aging and longevity.
All Articles
A treatment for post-transplant infection unresponsive to available medications has been approved by the FDA
56 % of those treated by Livtencity for 8 weeks manifested CMV DNA concentrations levels below a measurable level.
.jpg)
Post-transplant patients take immunosuppressants, so their immune system does not reject the transplant. Their system is therefore vulnerable to cytomegalovirus (CMV), a virus from the herpes family. Between 20% and 60% of patients who received solid organ transplant develop a symptomatic CMV, and this infection deemed very dangereous and untreatable. Until now.
The U.S. Food and Drug Administration (FDA) approved Livtencity to treat patients with post-transplant CMV infection that resist available treatment. This drug blocks viral replication by preventing the activity of the human cytomegalovirus enzyme pUL97.
The study consisted of 352 transplant recipients with treatment-resistant CMV who received Livtencity or other, currently used, antiviral treatment. 56 % of those treated by Livtencity for 8 weeks manifested CMV DNA concentrations levels below a measurable level, versus 24% of patients treated with other antiviral drug
Source: FDA
Read this article now
Sign up to get immediate access to this article and professional education in longevity medicine.
Oops! Something went wrong while submitting the form.
OUR partnering associations
Post-transplant patients take immunosuppressants, so their immune system does not reject the transplant. Their system is therefore vulnerable to cytomegalovirus (CMV), a virus from the herpes family. Between 20% and 60% of patients who received solid organ transplant develop a symptomatic CMV, and this infection deemed very dangereous and untreatable. Until now.
The U.S. Food and Drug Administration (FDA) approved Livtencity to treat patients with post-transplant CMV infection that resist available treatment. This drug blocks viral replication by preventing the activity of the human cytomegalovirus enzyme pUL97.
The study consisted of 352 transplant recipients with treatment-resistant CMV who received Livtencity or other, currently used, antiviral treatment. 56 % of those treated by Livtencity for 8 weeks manifested CMV DNA concentrations levels below a measurable level, versus 24% of patients treated with other antiviral drug
Source: FDA
Article reviewed by
Close
Dr. Ana Baroni MD. Ph.D.
Scientific & Medical Advisor
Quality Garant
Ana has over 20 years of consultancy experience in longevity, regenerative and precision medicine. She has a multifaceted understanding of genomics, molecular biology, clinical biochemistry, nutrition, aging markers, hormones and physical training. This background allows her to bridge the gap between longevity basic sciences and evidence-based real interventions, putting them into the clinic, to enhance the healthy aging of people. She is co-founder of Origen.life, and Longevityzone. Board member at Breath of Health, BioOx and American Board of Clinical Nutrition. She is Director of International Medical Education of the American College of Integrative Medicine, Professor in IL3 Master of Longevity at Barcelona University and Professor of Nutrigenomics in Nutrition Grade in UNIR University.
DISCOVER
HealthyLongevity.guide
Professional science-based education
250+ Articles, video lectures, webinars
Community of 1000+ verified professionals
.jpg)
